跳至主要内容

Medicilon was selected into the first batch of Shanghai innovative enterprise headquarters

 On December 5, the awarding ceremony for the first batch of Shanghai innovative enterprise headquarters was held.  Zheng Gong, Deputy Secretary of the Shanghai Municipal Party Committee and Mayor, awarded plaques to 40 innovative enterprise headquarters and took a group photo.  Shanghai Medicilon Inc. (Medicilon) has become one of the first 10 biopharmaceutical companies selected as Shanghai's innovative enterprise headquarters.  This is the first time that Shanghai has independently recognized the headquarters of innovative enterprises, providing support to accelerate the development of Shanghai's innovative economy and build a technological innovation center with global influence.  This honor signifies that Medicilon's performance in technological innovation in new drug research and development has been highly recognized by the Shanghai Municipal Government.

Medicilon was selected into the first batch of Shanghai innovative enterprise headquarters.webp

The 40 innovative enterprise headquarters awarded licenses this time cover key industrial fields such as integrated circuits, biopharmaceutical, artificial intelligence, and digital economy.  It mainly presents the following characteristics:

One is strong leadership.  The licensed companies are mainly leading companies and technological innovation leaders in their respective industries. More than 90% of the company's products and services rank among the top in domestic and global market shares, and have strong industry position.

Second is strong innovation ability.  Licensed companies invest heavily in R&D. More than 50% of them have Class I new drugs or “first-of-its-kind” products domestically or globally, and more than 10% of them have won national or local science and technology progress awards.

Third is high growth potential.  The licensing companies are all market entities with good development momentum in recent years.  In recent years, 22 companies have been listed globally, showing strong development vitality. More than 60% of the companies have achieved a compound growth rate of more than 30% in operating income in the past three years, achieving rapid growth.

Fourth is the distinct agglomeration development . The regional agglomeration effect of licensed enterprises is relatively consistent with the development positioning of strategic emerging industry clusters in each district.

In addition, all licensing companies have more than two branches or subsidiaries outside Shanghai. The Shanghai headquarters has complex and multiple functions such as management, settlement, and R&D.  Most companies have also achieved global layout.

As one of the first batch of innovative enterprise headquarters selected in Shanghai, Medicilon has focused on the field of pre-clinical research and development of biomedicine since its establishment in 2004, focusing on the needs of new drug research and development.  With its innovative R&D technology and hard-core R&D strength, Medicilon continues to empower the development of the biopharmaceutical industry by focusing on cutting-edge fields such as nucleic acid drugs, cellular immunity, mRNA, PROTAC, ADC, and bi/multispecific antibodies, which integrates a one-stop biopharmaceutical preclinical R&D service platform.

According to the "Shanghai Innovative Enterprise Headquarters Recognition and Reward Management Measurement" issued on February 22, 2023, Medicilon will subsequently enjoy a number of preferential policies such as financial support, talent introduction, and tax incentives provided by the Shanghai Municipal Government.  These will further help Medicilon to show more achievements in empowering the research and development of new drugs.

Being recognized as one of the first batch of innovative enterprise headquarters in Shanghai is not only an affirmation of Medicilon's efforts in empowering innovative drug research and development in the past nearly two decades, but also trust in the company's future development.  This honor will encourage Medicilon to continue to establish a hard technology moat and make greater contributions to promoting the innovation and development of biopharmaceutical in Shanghai and China.

About Innovative Enterprise Headquarters
In order to accelerate the development of Shanghai's innovative economy, the Shanghai Municipal Government encourages various innovative entities such as high-tech enterprises, specialized new enterprises, and corporate technology centers to further improve their capabilities, accelerate the creation of composite enterprise headquarters, and provide support for the construction of a technological innovation center with global influence.  The innovative enterprise headquarters focuses on key areas of strategic emerging industries, independently owns the core intellectual property rights of domestically and internationally influential products or services locally, and leads the industry in overall technical level and innovation capabilities, have important advantages and high growth in market competition, make an important contribution to local economic and social development or play a leading role, and have control or exercise management rights over their cross-regional branches or businesses).

标签：

评论

发表评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...
发表评论
阅读全文

What is Toxicokinetics?

Toxicokinetics  is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms  toxicokinetics ,  pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...
发表评论
阅读全文